ClinicaliQ Trial Snapshot
- Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials — Active Not Recruiting • Phase III • NCT05335876.
- Patients who received OAV101 for spinal muscular atrophy are being monitored for five years to check long-term safety and effectiveness.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a global, prospective, multi-center study that is designed to assess the long-term safety and efficacy of OAV101 in patients who participated in an OAV101 clinical trial. The assessments of safety and efficacy in Study COAV101A12308 will continue for 5 years after enrollment in this study. Conditions: Spinal Muscular Atrophy (SMA) Interventions: onasemnogene abeparvovec Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 20 participants